These results indicate that CCDC3 can alleviate HFD-induced hepatic steatosis by inhibiting the expression of PPAR-gamma, SCD1, CD36, Serbp1C in a short-term period post CCDC3 injection via i.v, suggesting a therapeutic potential of this secreted protein for fatty livers, though its underlying mechanism(s) still remains to be elucidated. This evidence concerns the gene PPARG and fatty liver disease.